263 related articles for article (PubMed ID: 36759899)
1. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
[TBL] [Abstract][Full Text] [Related]
2. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
[TBL] [Abstract][Full Text] [Related]
4. Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas.
Panwalkar P; Tamrazi B; Dang D; Chung C; Sweha S; Natarajan SK; Pun M; Bayliss J; Ogrodzinski MP; Pratt D; Mullan B; Hawes D; Yang F; Lu C; Sabari BR; Achreja A; Heon J; Animasahun O; Cieslik M; Dunham C; Yip S; Hukin J; Phillips JJ; Bornhorst M; Griesinger AM; Donson AM; Foreman NK; Garton HJL; Heth J; Muraszko K; Nazarian J; Koschmann C; Jiang L; Filbin MG; Nagrath D; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Allis CD; Chinnaiyan AM; Lunt SY; Blüml S; Judkins AR; Venneti S
Sci Transl Med; 2021 Oct; 13(614):eabc0497. PubMed ID: 34613815
[TBL] [Abstract][Full Text] [Related]
5. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
7. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
[TBL] [Abstract][Full Text] [Related]
8. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
9. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
Jain SU; Do TJ; Lund PJ; Rashoff AQ; Diehl KL; Cieslik M; Bajic A; Juretic N; Deshmukh S; Venneti S; Muir TW; Garcia BA; Jabado N; Lewis PW
Nat Commun; 2019 May; 10(1):2146. PubMed ID: 31086175
[TBL] [Abstract][Full Text] [Related]
10. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis.
Harutyunyan AS; Krug B; Chen H; Papillon-Cavanagh S; Zeinieh M; De Jay N; Deshmukh S; Chen CCL; Belle J; Mikael LG; Marchione DM; Li R; Nikbakht H; Hu B; Cagnone G; Cheung WA; Mohammadnia A; Bechet D; Faury D; McConechy MK; Pathania M; Jain SU; Ellezam B; Weil AG; Montpetit A; Salomoni P; Pastinen T; Lu C; Lewis PW; Garcia BA; Kleinman CL; Jabado N; Majewski J
Nat Commun; 2019 Mar; 10(1):1262. PubMed ID: 30890717
[TBL] [Abstract][Full Text] [Related]
11. H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
Jain SU; Rashoff AQ; Krabbenhoft SD; Hoelper D; Do TJ; Gibson TJ; Lundgren SM; Bondra ER; Deshmukh S; Harutyunyan AS; Juretic N; Jabado N; Harrison MM; Lewis PW
Mol Cell; 2020 Nov; 80(4):726-735.e7. PubMed ID: 33049227
[TBL] [Abstract][Full Text] [Related]
12. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
13. Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
Sarthy JF; Meers MP; Janssens DH; Henikoff JG; Feldman H; Paddison PJ; Lockwood CM; Vitanza NA; Olson JM; Ahmad K; Henikoff S
Elife; 2020 Sep; 9():. PubMed ID: 32902381
[TBL] [Abstract][Full Text] [Related]
14. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
[TBL] [Abstract][Full Text] [Related]
15. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
bioRxiv; 2024 May; ():. PubMed ID: 38798502
[TBL] [Abstract][Full Text] [Related]
16. Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
Sanders LM; Cheney A; Seninge L; van den Bout A; Chen M; Beale HC; Kephart ET; Pfeil J; Learned K; Lyle AG; Bjork I; Haussler D; Salama SR; Vaske OM
Gigascience; 2020 Dec; 9(12):. PubMed ID: 33319914
[TBL] [Abstract][Full Text] [Related]
17. Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D'Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA
Sci Rep; 2023 Mar; 13(1):3775. PubMed ID: 36882456
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.
Zang D; Dong Z; Liu Y; Chen Q
BMC Neurol; 2024 Feb; 24(1):74. PubMed ID: 38383423
[TBL] [Abstract][Full Text] [Related]
19. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas.
Bechet D; Gielen GG; Korshunov A; Pfister SM; Rousso C; Faury D; Fiset PO; Benlimane N; Lewis PW; Lu C; David Allis C; Kieran MW; Ligon KL; Pietsch T; Ellezam B; Albrecht S; Jabado N
Acta Neuropathol; 2014 Nov; 128(5):733-41. PubMed ID: 25200321
[TBL] [Abstract][Full Text] [Related]
20. Histone H3K27M Mutation in Brain Tumors.
El-Hashash AHK
Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]